Dr. Abbey Discusses How Vorolanib Could Shift the Treatment Approach for Diabetic Macular Edema in New Retinal Physician Article
Texas Retina’s Ashkan M. Abbey, MD, served as a principal site investigator for the Phase II VERONA clinical trial evaluating the efficacy and safety of the vorolanib intravitreal insert (EYP-1901) in diabetic
read more Dr. Abbey Shares 36-Month Results of Pegcetacoplan Treatment for Geographic Atrophy in AMD
On behalf of the investigators for the OAKS, DERBY, and GALE clinical trials, Texas Retina’s Director of Clinical Research for Dallas, Ashkan Abbey, MD, co-authored an article titled, “Pegcetacoplan Treatment for Geographic
read more
Texas Retina Clinical Research Coordinator Rachel McCullough Participates in Panel Discussion for LUGANO and LUCIA Clinical Trials
At a recent meeting in San Antonio, Texas Retina Clinical Research Coordinator Rachel McCullough participated in a panel discussion with study coordinators for EyePoint Pharmaceuticals’ pivotal Phase III LUGANO and LUCIA clinical
read more
Dr. Abbey Serves as Guest Editor for Latest Issue of Retina Today
Texas Retina’s Ashkan M. Abbey, MD, served as guest medical editor for the January/February 2025 issue of Retina Today along with Christina Y. Weng, MD, from Baylor College of Medicine. Retina Today
read more
Dr. Abbey Discusses Injectable Retina Treatments on AAO Podcast
On a recent episode of the American Academy of Ophthalmology’s “Experts InSight” podcast, Texas Retina’s Ashkan Abbey, MD, joined Ehsan Rahimy, MD, and host Jay Shridhar, MD, to discuss recent developments in
read more
Texas Retina Research Team Publishes New Study on Wet AMD Treatment
Texas Retina’s Ashkan Abbey, MD; Paige Abril, BS; and Rachel McCullough, BS, recently published a retrospective study in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina titled, “Outcomes of Intravitreal Aflibercept
read more
Dr. Abbey Discusses Latest Dry AMD Treatment Research on New Podcast Episode
While anti-VEGF injections are widely used to treat patients with wet age-related macular degeneration (AMD), there have been limited treatment options available for dry AMD other than AREDS vitamin formulations and lifestyle
read more Dr. Abbey Reports on New Method to Measure Retinal Fluid After Treatment with Faricimab for Wet AMD
Texas Retina’s Ashkan M. Abbey, MD, recently co-authored an article in the medical journal Eye on the use of a novel deep-learning algorithm to quantify retinal fluid changes in patients treated with
read more
Dr. Abbey Doses First Patient in Phase III LUGANO Clinical Trial of Duravyu for Wet AMD
Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, recently dosed the first patient in the Phase III LUGANO clinical trial of Duravyu (formerly EYP-1901) for the treatment of
read more
Dr. Abbey Taught a Course at the American Academy of Ophthalmology 2024 Annual Meeting
For the fifth year, Texas Retina’s Ashkan M. Abbey, MD, taught a continuing medical education (CME) course titled, “Secondary IOL Techniques for Retinal Specialists,” at the annual meeting of the American Academy
read more